Stocks Hit Session Lows; Biotech, Homebuilders Lead Slump
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall St set for lower open as Big Tech earnings rekindle AI spending worries, oil jumps
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- RTX stock jumps as company lifts guidance after Q2 beat
- Dollar hits fresh 40-year high versus yen, edges higher against euro
Biogen Second Quarter 2015 Revenues Increase 7% to $2.6 Billion
July 24, 2015 6:50 AM EDTTECFIDERA® now the most prescribed oral MS therapy globally
Sites initiated for aducanumab Phase 3 studies for Alzheimers disease
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Biogen Inc. (NASDAQ: BIIB) today reported second quarter 2015 results, including revenues of $2.6 billion, a 7% increase compared to the second quarter of 2014. Non-GAAP diluted earnings per share (EPS) for the second quarter of 2015 were $4.22, an increase of 21% over the second quarter of 2014. Non-GAAP net income attributable to Biogen for the second quarter of 2015 was $995 million, an increase of 20% over the second... More
